Related Experiment Video

Updated: Jun 24, 2026

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models
05:33

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Published on: September 6, 2024

Peroxisome proliferator-activating receptors: a new way to treat melanoma?

Dirk Schadendorf1

  • 1Department of Dermatology, Venerology, and Allergology, University Hospital Essen, Essen, Germany. dirk.schadendorf@uk-essen.de

The Journal of Investigative Dermatology
|April 17, 2009
PubMed

Insights

Peroxisome proliferator-activated receptor-gamma (PPARgamma) ligands show potential for melanoma treatment. Researchers found that ciglitazone, a PPARgamma activator, demonstrated antimelanoma effects in laboratory and animal studies.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Peroxisome proliferator-activated receptor-gamma (PPARgamma) ligands, primarily used for diabetes, are being investigated for anticancer properties.
  • Evidence suggests a potential therapeutic role for PPARgamma ligands in melanoma treatment.
  • The ability to separate apoptotic effects from PPARgamma activation offers a strategy for targeted cancer therapy.

Purpose of the Study:

  • To investigate the potential of PPARgamma-activating ligands as novel agents for melanoma treatment.
  • To evaluate the antimelanoma efficacy of ciglitazone, a synthetic PPARgamma ligand.
  • To explore the dissociation of apoptotic effects from PPARgamma activation in the context of melanoma.

Main Methods:

  • In vitro assays to assess the effects of ciglitazone on melanoma cells.
  • In vivo studies using animal models to evaluate the antimelanoma activity of ciglitazone.
  • Analysis of PPARgamma activation and its correlation with apoptotic effects.

Main Results:

  • Ciglitazone demonstrated significant antimelanoma effects in vitro.
  • In vivo studies confirmed the efficacy of ciglitazone against melanoma.
  • The study provides evidence for the dissociation of apoptotic effects from PPARgamma activation.

Conclusions:

  • Ciglitazone exhibits promising antimelanoma activity, supporting its potential as a targeted anticancer agent.
  • PPARgamma ligands represent a viable therapeutic avenue for melanoma treatment.
  • Targeting PPARgamma pathways offers a novel strategy for developing molecularly targeted melanoma therapies.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues08:06

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues

Published on: July 8, 2020

Related Concept Videos

Peroxisomes01:24

Peroxisomes

Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...